PCSK9-IN-10
Product Specifications
CAS Number
368434-98-4
Target
Serine/threonin kinase, LDLR, Others
Related Pathways
Cell Cycle/Checkpoint, Others, Metabolism
Purity
0.9906
Bioactivity
PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 μM. By enhancing the expression of Low-Density Lipoprotein Receptor (LDLR) protein and reducing PCSK9 expression, PCSK9-IN-10 effectively decreases atherosclerosis progression. This compound holds promise for hyperlipidemia research applications.
Smiles
COCCNc1nc2n(C)c(=O)n(C)c(=O)c2n1Cc1cccc(OC)c1
Molecular Formula
C18H23N5O4
Molecular Weight
373.41
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
AP1C20-01 1 mg
Recombinant Canine Bone Morphogenetic Protein 4 (BMP4), N-His
Sign In for Pricing
View Details AP1C20-02 10 µg
Recombinant Canine Bone Morphogenetic Protein 4 (BMP4), N-His
Sign In for Pricing
View Details AP1C20-03 200 µg
Recombinant Canine Bone Morphogenetic Protein 4 (BMP4), N-His
Sign In for Pricing
View Details AP1C20-04 5 mg
Recombinant Canine Bone Morphogenetic Protein 4 (BMP4), N-His
Sign In for Pricing
View Details AP1C20-05 50 µg
Recombinant Canine Bone Morphogenetic Protein 4 (BMP4), N-His
Sign In for Pricing
View Details 